Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 15/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401358 | 0.85 | CTSL (0.76) | FURINCTSLPRSS1PCSK6 | |
| SCHEMBL30074409 | 0.85 | CTSL (0.76) | FURINCTSLPRSS1PCSK6 | |
| Thymocartin SCHEMBL29355849 | 0.82 | NPY1R (0.50) | FURINCTSLPRSS1PCSK6NPY1R | |
| SCHEMBL29384677 | 0.80 | FURIN (0.63) | FURINCTSLPRSS1PCSK6NPY1R | |
| SCHEMBL29349719 | 0.78 | FURIN (0.60) | FURINNPY1RNPY2RNPY4R | |
| SCHEMBL6700441 | 0.78 | GSR (0.45) | FURINCTSLPCSK6 | |
| SCHEMBL6700436 | 0.78 | GSR (0.45) | FURINCTSLPCSK6 | |
| SCHEMBL31126783 | 0.78 | DPP8 (0.46) | FURINCTSLPCSK6NPY1RNPY2R | |
| SCHEMBL31470824 | 0.77 | CYP1A2 (0.56) | NPY1RNPY2RNPY4R | |
| SCHEMBL29394951 | 0.77 | CYP1A2 (0.56) | NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129370-A1 | METHOD FOR REDUCING HEPATIC TRIGLYCERIDES | ADAERATA, LIMITED PARTNERSHIP (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4475854-A1 | METHOD FOR REDUCING HEPATIC TRIGLYCERIDES | Adaerata, Limited Partnership (CA) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023150869-A1 | METHOD FOR REDUCING HEPATIC TRIGLYCERIDES | ADAERATA, LIMITED PARTNERSHIP (CA) | 2023-08-17 | — | — | WO | disclosed |
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP ASSET V, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4125897-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP Asset V, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666567-A | Furin inhibitors for the treatment of coronavirus infection | BP资产V股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022159787-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | FURIN, ACE, ACE2 | FURIN 1/4885CTSL 18/4885PRSS1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.